Evidence for a functional genetic polymorphism of the Rho-GTPase Rac1. Implication in azathioprine response?

Pharmacogenetics and Genomics

Volumn 21, Issue 6, 2011, Pages 313-324

  Bourgine, Joanna ^a   Garat, Anne ^a   Allorge, Delphine ^a   Crunelle Thibaut, Aurélie ^a   Lo Guidice, Jean Marc ^a   Colombel, Jean Frédéric ^b   Broly, Franck ^a   Billaut Laden, Ingrid ^a  

^a France Institut Pasteur de Lille   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

adverse effects; azathioprine response; inflammatory bowel disease; Rac1 genetic polymorphism; Rac1 promoter; thiopurine drugs

Indexed keywords

AZATHIOPRINE; RAC1 PROTEIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; THIOPURINE METHYLTRANSFERASE;

ADULT; ARTICLE; BLOOD TOXICITY; CAUCASIAN; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DNA DETERMINATION; ENTERITIS; FEMALE; GENE; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC SCREENING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; RAC1 GENE; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; TANDEM REPEAT; TREATMENT RESPONSE; ULCERATIVE COLITIS; WILD TYPE;

EID: 79955904447     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e3283449200     Document Type: Article

References (53)

1. Elion GB. The purine path to chemotherapy. Science 1989; 244:41-47. (Pubitemid 19130741)
2. Weinshilboum R. Thiopurine pharmacogenetics: clinical and molecular studies of thiopurine methyltransferase. Drug Metab Dispos 2001; 29:601-605. (Pubitemid 32275544)
3. Krynetski E, Evans WE. Drug methylation in cancer therapy: lessons from the TPMT polymorphism. Oncogene 2003; 22:7403-7413. (Pubitemid 37487166)
4. Derijks LJ, Wong DR. Pharmacogenetics of thiopurines in inflammatory bowel disease. Curr Pharm Des 2010; 16:145-154.
5. Ansari A, Hassan C, Duley J, Marinaki A, Shobowale-Bakre EM, Seed P, et al. Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. Aliment Pharmacol Ther 2002; 16: 1743-1750.
6. Schwab M, Schaffeler E, Marx C, Fischer C, Lang T, Behrens C, et al. Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine-S-methyltransferase polymorphism. Pharmacogenetics 2002; 12:429-436. (Pubitemid 34918619)
7. Marinaki AM, Ansari A, Duley JA, Arenas M, Sumi S, Lewis CM, et al. Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). Pharmacogenetics 2004; 14:181-187. (Pubitemid 38373112)
8. Connell WR, Kamm MA, Ritchie JK, Lennard-Jones JE. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993; 34:1081-1085. (Pubitemid 23245359)
9. Lennard L. TPMT in the treatment of Crohn's disease with azathioprine. Gut 2002; 51:143-146. (Pubitemid 34791433)
10. Eklund BI, Moberg M, Bergquist J, Mannervik B. Divergent activities of human glutathione transferases in the bioactivation of azathioprine. Mol Pharmacol 2006; 70:747-754. (Pubitemid 44092335)
11. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980; 32:651-662. (Pubitemid 10061685)
12. Relling MV, Hancock ML, Rivera GK, Sandlund JT, Ribeiro RC, Krynetski EY, et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 1999; 91:2001-2008.
13. Colombel JF, Ferrari N, Debuysere H, Marteau P, Gendre JP, Bonaz B, et al. Genotypic analysis of thiopurine-S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000; 118:1025-1030. (Pubitemid 30346978)
14. Dubinsky MC, Yang H, Hassard PV, Seidman EG, Kam LY, Abreu MT, et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002; 122:904-915. (Pubitemid 34267273)
15. Roberts RL, Gearry RB, Barclay ML, Kennedy MA. IMPDH1 promoter mutations in a patient exhibiting azathioprine resistance. Pharmacogenomics J 2007; 7:312-317. (Pubitemid 47484772)
16. Schaeffeler E, Fischer C, Brockmeier D, Wernet D, Moerike K, Eichelbaum M, et al. Comprehensive analysis of thiopurine-S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics 2004; 14:407-417. (Pubitemid 38971231)
17. Krynetskaia NF, Krynetski EY, Evans WE. Human RNase H-mediated RNA cleavage from DNA-RNA duplexes is inhibited by 6-deoxythioguanosine incorporation into DNA. Mol Pharmacol 1999; 56:841-848. (Pubitemid 29491188)
18. Somerville L, Krynetski EY, Krynetskaia NF, Beger RD, Zhang W, Marhefka CA, et al. Structure and dynamics of thioguanine-modified duplex DNA. J Biol Chem 2003; 278:1005-1011. (Pubitemid 36790778)
19. Tiede I, Fritz G, Strand S, Poppe D, Dvorsky R, Strand D, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4 + T lymphocytes. J Clin Invest 2003; 111:1133-1145. (Pubitemid 36519931)
20. Poppe D, Tiede I, Fritz G, Becker C, Bartsch B, Wirtz S, et al. Azathioprine suppresses ezrin-radixin-moesin-dependent T cell-APC conjugation through inhibition of Vav guanosine exchange activity on Rac proteins. J Immunol 2006; 176:640-651. (Pubitemid 43023313)
21. Katsanos KH, Tsianos EV. Explaining the unexplaining leucopenia in azathioprine treatment. Ann of Gastroenterol 2006; 19:141-142. (Pubitemid 47381928)
22. Wittinghofer A, Nassar N. How Ras-related proteins talk to their effectors. Trends Biochem Sci 1996; 21:488-491. (Pubitemid 27018818)
23. Zohn IM, Campbell SL, Khosravi-Far R, Rossman KL, Der CJ. Rho family proteins and Ras transformation: the RHOad less traveled gets congested. Oncogene 1998; 17:1415-1438. (Pubitemid 28458410)
24. Matos P, Skaug J, Marques B, Beck S, Veŕissimo F, Gespach C, et al. Small GTPase Rac1: structure, localization, and expression of the human gene. Biochem Biophys Res Commun 2000; 277:741-751.
25. Schnelzer A, Prechtel D, Knaus U, Dehne K, Gerhard M, Graeff H, et al. Rac1 in human breast cancer: overexpression, mutation analysis, and characterization of a new isoform, Rac1b. Oncogene 2000; 19:3013-3020. (Pubitemid 30389092)
26. Matos P, Collard JG, Jordan P. Tumor-related alternatively spliced Rac1b is not regulated by Rho-GDP dissociation inhibitors and exhibits selective downstream signaling. J Biol Chem 2003; 278:50442-50448. (Pubitemid 37548889)
27. Fiegen D, Haeusler LC, Blumenstein L, Herbrand U, Dvorsky R, Vetter IR, et al. Alternative splicing of Rac1 generates Rac1b, a self-activating GTPase. J Biol Chem 2004; 279:4743-4749. (Pubitemid 38199069)
28. Kugler MC, Gerhard M, Schnelzer A, Borzym K, Reinhardt R, Schmitt M, et al. Isolation and characterization of Rac1 pseudogenes (psi1Rac1-psi4Rac1) in the human genome. Gene 2004; 341:189-197. (Pubitemid 39335894)
29. Jordan P, Brazao R, Boavida MG, Gespach C, Chastre E. Cloning of a novel human Rac1b splice variant with increased expression in colorectal tumors. Oncogene 1999; 18:6835-6839.
30. Al Hadithy AF, De Boer NK, Derijks LJ, Escher JC, Mulder CJ, Brouwers JR. Thiopurines in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring and clinical recommendations. Dig Liver Dis 2005; 37:282-297. (Pubitemid 41070528)
31. Quandt K, Frech K, Karas H, Wingender E, Werner T. MatInd and MatInspector: new fast and versatile tools for detection of consensus matches in nucleotide sequence data. Nucleic Acids Res 1995; 23:4878-4884. (Pubitemid 3008389)
32. Heinemeyer T, Wingender E, Reuter I, Hermjakob H, Kel AE, Kel OV, et al. Databases on transcriptional regulation: TRANSFAC, TRRD, and COMPEL. Nucleic Acids Res 1998; 26:364-370.
33. Den Dunnen JT, Antonarakis SE. Nomenclature for the description of human sequence variations. Hum Genet 2001; 109:121-124. (Pubitemid 32743202)
34. Hall A. Rho GTPases and the actin cytoskeleton. Science 1998; 279: 509-514. (Pubitemid 28067271)
35. Karnoub AE, Symons M, Campbell SL, Der CJ. Molecular basis for Rho GTPase signaling specificity. Breast Cancer Res Treat 2004; 84:61-71. (Pubitemid 38388861)
36. Koch O, Kwiatkowski DP, Udalova IA. Context-specific functional effects of IFNGR1 promoter polymorphism. Hum Mol Genet 2006; 15:1475-1481.
37. Jones KA, Kadonaga JT, Luciw PA, Tjian R. Activation of the AIDS retrovirus promoter by the cellular transcription factor, Sp1. Science 1986; 232: 755-759. (Pubitemid 16078720)
38. Siegfried Z, Eden S, Mendelsohn M, Feng X, Tsuberi BZ, Cedar H. DNA methylation represses transcription in vivo. Nat Genet 1999; 22:203-206. (Pubitemid 29264820)
39. Hagen G, Müller S, Beato M, Suske G. Sp1-mediated transcriptional activation is repressed by Sp3. EMBO J 1994; 13:3843-3851. (Pubitemid 24275030)
40. Ghayor C, Chadjichristos C, Herrouin JF, Ala-Kokko L, Suske G, Pujol JP, et al. Sp3 represses the Sp1-mediated transactivation of the human COL2A1 gene in primary and de-differentiated chondrocytes. J Biol Chem 2001; 276:36881-36895.
41. Suske G. The Sp-family of transcription factors. Gene 1999; 238:291-300. (Pubitemid 29446168)
42. Kimura N, Takamatsu N, Yaoita Y, Osamura RY, Kimura N. Identification of transcriptional regulatory elements in the human somatostatin receptor sst2 promoter and regions including estrogen response element half-site for estrogen activation. J Mol Endocrinol 2008; 40:75-91. (Pubitemid 351279511)
43. Williams AO, Isaacs RJ, Stowell KM. Down-regulation of human topoisomerase IIa expression correlates with relative amounts of specificity factors Sp1 and Sp3 bound at proximal and distal promoter regions. BMC Mol Biol 2007; 8:36.
44. Rui X, Tsao J, Scheys JO, Hammer GD, Schimmer BP. Contributions of specificity protein-1 and steroidogenic factor 1 to Adcy4 expression in Y1 mouse adrenal cells. Endocrinology 2008; 149:3668-3678. (Pubitemid 351919578)
45. Ou XM, Chen K, Shih JC. Dual functions of transcription factors, transforming growth factor-beta-inducible early gene (TIEG)2 and Sp3, are mediated by CACCC element and Sp1 sites of human monoamine oxidase (MAO) B gene. J Biol Chem 2004; 279:21021-21028. (Pubitemid 38656503)
46. Zelinkova Z, Derijks LJ, Stokkers PC, Vogels EW, van Kampen AH, Curvers WL, et al. Inosine triphosphate pyrophosphatase and thiopurine s-methyltransferase genotypes relationship to azathioprine-induced myelosuppression. Clin Gastroenterol Hepatol 2006; 4:44-49. (Pubitemid 43129523)
47. Zelinkova Z, Derijks LJ, Stokkers P, Vogels E, van Kampen A, Curvers WL, et al. Digestive Disease Week: inosine triphosphate pyrophosphatase gene mutation predicts myelosuppression in IBD patients treated with azathioprine. Gastroenterology 2004; 126:A112.
48. Von Ahsen N, Von Ahsen N, Armstrong VW, Behrens C, Von Tirpitz C, Stallmach A, et al. Association of inosine triphosphatase 94C < A and thiopurine S-methyltransferase deficiency with adverse events and study drop-outs under azathioprine therapy in a prospective Crohn disease study. Clin Chem 2005; 51:2282-2288. (Pubitemid 41692571)
49. Gearry RB, Roberts RL, Barclay ML, Kennedy MA. Lack of association between the ITPA 94C>A polymorphism and adverse effects from azathioprine. Pharmacogenetics 2004; 14:779-781. (Pubitemid 39552794)
50. Van Dieren JM, Van Vuuren AJ, Kusters JG, Nieuwenhuis EE, Kuipers EJ, Van der Woude CJ. ITPA genotyping is not predictive for the development of side effects in AZA treated inflammatory bowel disease patients. Gut 2005; 54:1664. (Pubitemid 41531793)
51. Hindorf U, Lindqvist M, Peterson C, Söderkvist P, Ström M, Hjortswang H, et al. Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease. Gut 2006; 55:1423-1431. (Pubitemid 44476786)
52. Van Dieren JM, Hansen BE, Kuipers EJ, Nieuwenhuis EE, Van der Woude CJ. Meta-analysis: inosine triphosphate pyrophosphatase polymorphisms and thiopurine toxicity in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2007; 26:643-652. (Pubitemid 47246201)
53. Bierau J, Lindhout M, Bakker JA. Pharmacogenetic significance of inosine triphosphatase. Pharmacogenomics 2007; 8:1221-1228. (Pubitemid 47578231)